Announcements Trials
Browse Landscape

Phase

Phase 2 2

Status

Terminated 1Completed 1

Sponsor Class

OTHER 2

Study Type

Interventional 2

Sponsor

Cancer Type

Dermatologic 1CNS 1Breast 1

Conditions

Melanoma 1Central Nervous System Diseases 1Breast Neoplasms 1Brain Neoplasms 1

Interventions

Cyclophosphamide 548pembrolizumab 385Radiotherapy 363Bevacizumab 360Carboplatin 351Rituximab 315Cisplatin 300Gemcitabine 297Paclitaxel 288Dexamethasone 272Docetaxel 271fludarabine phosphate 241Doxorubicin 231Nivolumab 220Etoposide 209Cytarabine 203Lenalidomide 201fludarabine 191Oxaliplatin 191Fluorouracil 190Melphalan 189Filgrastim 188Capecitabine 175Calcium Dobesilate 172Radiosurgery 167Erlotinib Hydrochloride 167Methotrexate 163Bortezomib 162Granulocyte Colony-Stimulating Factor 154Whole-Body Irradiation 144

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
OTHER × Has results × sagopilone × Clear all
NCT00598507 2013-12-11

Phase II Trial Of ZK-EPO (ZK 219477) (Sagopilone) In Metastatic Melanoma

H. Lee Moffitt Cancer Center and Research Institute

Phase 2 Completed
35 enrolled 8 charts
Dermatologic

Melanoma

NCT00496379 2013-03-14

ZK219477 (Sagopilone) in Patients With Breast Cancer and Brain Metastases

Dana-Farber Cancer Institute

Phase 2 Terminated
15 enrolled 10 charts
BreastCNS

Brain Neoplasms, Breast Neoplasms, Central Nervous System Diseases

Data powered by HemOnc (CC BY 4.0) Colophon âš¡